Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Chiara Paoli, Paola Guglielmelli, Francesco Mannelli, Miriam Borella, Vittorio Rosti, Elisa Rumi, Maria Chiara Finazzi, Oscar Borsani, Carmela Mannarelli, Maria Esposito, Mario Xhani, Lisa Pieri, Tiziano Barbui, Alessandro Rambaldi, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 6840–6841.

https://doi.org/10.1182/blood-2022-156566

Published: 2022

Journal Articles

Increased B4GALT1 expression is associated with platelet surface galactosylation and thrombopoietin plasma levels in MPNs

Christian A. Di Buduo, Silvia Giannini, Vittorio Abbonante, Vittorio Rosti, Karin M. Hoffmeister, Alessandra Balduini

Blood (2021) 137 (15): 2085–2089.

https://doi.org/10.1182/blood.2020007265

Published: 2021

Includes: Supplemental data

Journal Articles

Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms

Christian A. Di Buduo, Vittorio Abbonante, Caroline Marty, Francesco Moccia, Elisa Rumi, Daniela Pietra, Paolo M. Soprano, Dmitry Lim, Daniele Cattaneo, Alessandra Iurlo, Umberto Gianelli, Giovanni Barosi, Vittorio Rosti, Isabelle Plo, Mario Cazzola, Alessandra Balduini

Blood (2020) 135 (2): 133–144.

https://doi.org/10.1182/blood.2019001103

Published: 2020

Includes: Supplemental data

Journal Articles

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Blood (2019) 134 (Supplement_1): 2943.

https://doi.org/10.1182/blood-2019-124865

Published: 2019

Journal Articles

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Alessandro Malara, PhD, Cristian Gruppi, PhD, Margherita Massa, Vittorio Rosti, MD, Giovanni Barosi, Alessandra Balduini, MD

Blood (2019) 134 (Supplement_1): 1688.

https://doi.org/10.1182/blood-2019-130735

Published: 2019

Journal Articles

Homozygosity for -2518 G Allele Variant of MCP-1 Predisposes to Adverse Presentation and Outcome in Primary Myelofibrosis

Elena Masselli, MD, Cecilia Carubbi, PhD, Giulia Pozzi, MS, Antonio Percesepe, MD PhD, Rita Campanelli, Laura Villani, Giuliana Gobbi, PhD, Vittorio Rosti, MD, Margherita Massa, Giovanni Barosi, Marco Vitale, MD

Blood (2019) 134 (Supplement_1): 1689.

https://doi.org/10.1182/blood-2019-122750

Published: 2019

Journal Articles

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Chiara Paoli, PhD, Paola Guglielmelli, MD PhD, Francesco Mannelli, MD, Lara Mannelli, MD, Vittorio Rosti, MD, Maria Chiara Finazzi, MD, Elisa Rumi, MD, Marco Ruggeri, Alessandro Pancrazzi, PhD, Carmela Mannarelli, PhD, Guido Finazzi, MD, Maria Luisa Ferrari, BSc, Laura Lissandrini, BSc, Duccio Fantoni, RN, Giovanni Barosi, Mario Cazzola, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1662.

https://doi.org/10.1182/blood-2019-122837

Published: 2019

Journal Articles

Elevated Plasma sIL-2Rα Levels in Primary Myelofibrosis Play a Distinct Role on Disease Progression in JAK2V617F and Calr Mutants

Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Mara De Amici, Carlotta Abbà, MSc, Gianluca Viarengo, Laura Villani, Margherita Massa, Vittorio Rosti, MD

Blood (2019) 134 (Supplement_1): 1678.

https://doi.org/10.1182/blood-2019-125531

Published: 2019

Journal Articles

Shared and Distinctive Ultrastructural Abnormalities Expressed By Megakaryocytes in Bone Marrow and Spleen from Patients with Primary Myelofibrosis

Maria Zingariello, PhD, Vittorio Rosti, MD, Alessandro M. Vannucchi, MD, Paola Guglielmelli, MD PhD, Claudio Bardelli, PhD, Maria Mazzarini, Rosa Alba Rana, Giovanni Barosi, Anna Rita Rita Migliaccio, PhD

Blood (2019) 134 (Supplement_1): 4209.

https://doi.org/10.1182/blood-2019-123140

Published: 2019

Journal Articles

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Blood (2019) 134 (18): 1498–1509.

https://doi.org/10.1182/blood.2019000428

Published: 2019

Includes: Supplemental data

Journal Articles

Increased STAT5/STAT3 Intracellular Signaling in Circulating CD34+ Cells of Patients with PMF Correlates with Disease Severity

Carlotta Abbà, MSc, Rita Campanelli, Paolo Catarsi, Laura Villani, Vittorio Abbonante, PhD, Christian Andrea Di Buduo, PhD, Melania Antonietta Sesta, Vittorio Rosti, MD, Giovanni Barosi, MD, Margherita Massa

Blood (2018) 132 (Supplement 1): 4337.

https://doi.org/10.1182/blood-2018-99-114684

Published: 2018

Journal Articles

EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression

Alessandro Malara, PhD, Cristian Gruppi, PhD, Vittorio Abbonante, PhD, Daniele Cattaneo, MD, Luigi De Marco, MD, Alessandra Iurlo, Umberto Gianelli, MD, Andrés F Muro, PhD, Anil K Chauhan, PhD, Vittorio Rosti, MD, Giovanni Barosi, MD, Alessandra Balduini, MD

Blood (2018) 132 (Supplement 1): 1781.

https://doi.org/10.1182/blood-2018-99-116454

Published: 2018

Journal Articles

Abnormal Regulation of Intracellular Calcium in Human Megakaryocytes Contributes to the Pathophysiology of Calr-Mutant Myeloproliferative Neoplasms

Christian Andrea Di Buduo, PhD, Vittorio Abbonante, PhD, Elisa Rumi, MD, Daniela Pietra, PhD, Francesco Moccia, PhD, Giovanni Barosi, MD, Vittorio Rosti, MD, Mario Cazzola, Alessandra Balduini, MD

Blood (2018) 132 (Supplement 1): 1782.

https://doi.org/10.1182/blood-2018-99-116166

Published: 2018

Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Blood (2018) 132 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2018-99-115129

Published: 2018

Journal Articles

RUNX1 Expression Characterizes the Endothelial Cells from the Spleen and Bone Marrow of Patients with Primary Myelofibrosis

Rita Campanelli, Margherita Massa, Laura Villani, Paolo Catarsi, Carlotta Abbà, MSc, Elisabetta Dejana, Monica Corada, Federica Pisati, Giovanni Barosi, MD, Vittorio Rosti, MD

Blood (2018) 132 (Supplement 1): 5486.

https://doi.org/10.1182/blood-2018-99-114564

Published: 2018

Journal Articles

Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Blood (2017) 130 (Supplement 1): 321.

https://doi.org/10.1182/blood.V130.Suppl_1.321.321

Published: 2017

Journal Articles

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Blood (2017) 130 (Supplement 1): 322.

https://doi.org/10.1182/blood.V130.Suppl_1.322.322

Published: 2017

Journal Articles

Shared and Tissue-Specific Genetic Features of Primary Myelofibrosis, Hepatic Fibrosis, Idiopathic Pulmonary Fibrosis and Kidney Fibrosis

Anders B Dohlman, MS, Rosa S Kim, Hadassa Hirschfield, Lilian Varricchio, Fiorella Ciaffoni, Massimiliano Dall'ora, Yujin Hoshida, Naftali Kaminski, Giovanni Barosi, MD, Vittorio Rosti, MD, Scott Friedman, Ronald Hoffman, MD, Anna Rita Migliaccio, PhD

Blood (2017) 130 (Supplement 1): 4196.

https://doi.org/10.1182/blood.V130.Suppl_1.4196.4196

Published: 2017

Journal Articles

Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Blood (2017) 130 (Supplement 1): 4206.

https://doi.org/10.1182/blood.V130.Suppl_1.4206.4206

Published: 2017

Journal Articles

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

Alessandro M. Vannucchi, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Giada Rotunno, MSc, PhD, Carmela Mannarelli, MSc, PhD, Annalisa Pacilli, PhD, Animesh Pardanani, MBBS PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Curtis A. Hanson, MD, Francesco Mannelli, Rhett P. Ketterling, MD, Naseema Gangat, MBBS, Alessandro Rambaldi, MD Prof, Francesco Passamonti, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 200.

https://doi.org/10.1182/blood.V130.Suppl_1.200.200

Published: 2017

NARROW

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Increased B4GALT1 expression is associated with platelet surface galactosylation and thrombopoietin plasma levels in MPNs

Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Homozygosity for -2518 G Allele Variant of MCP-1 Predisposes to Adverse Presentation and Outcome in Primary Myelofibrosis

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Elevated Plasma sIL-2Rα Levels in Primary Myelofibrosis Play a Distinct Role on Disease Progression in JAK2V617F and Calr Mutants

Shared and Distinctive Ultrastructural Abnormalities Expressed By Megakaryocytes in Bone Marrow and Spleen from Patients with Primary Myelofibrosis

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Increased STAT5/STAT3 Intracellular Signaling in Circulating CD34+ Cells of Patients with PMF Correlates with Disease Severity

EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression

Abnormal Regulation of Intracellular Calcium in Human Megakaryocytes Contributes to the Pathophysiology of Calr-Mutant Myeloproliferative Neoplasms

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

RUNX1 Expression Characterizes the Endothelial Cells from the Spleen and Bone Marrow of Patients with Primary Myelofibrosis

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Shared and Tissue-Specific Genetic Features of Primary Myelofibrosis, Hepatic Fibrosis, Idiopathic Pulmonary Fibrosis and Kidney Fibrosis

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only